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Abstract
Background
Five to ten million persons, are infected by HTLV-1 of which 3% will develop HTLV-1-asso-
ciated myelopathy (HAM) a chronic, disabling inflammation of the spinal cord. Walking, a
fundamental, complex, multi-functional task is demanding of multiple body systems.
Restricted walking ability compromises activity and participation levels in people with HAM
(pwHAM). Therapy aims to improve mobility but validated measures are required to assess
change.
Study Design
Prospective observational study.
Objectives
To explore walking capacity in pwHAM, walking endurance using the 6 minute walk (6MW),
and gait speed, using the timed 10m walk (10mTW).
Setting
Out-patient setting in an inner London Teaching hospital.
Methods
Prospective documentation of 10mTW and 6MW distance; walking aid usage and pain
scores measured twice, a median of 18 months apart.
Results
Data analysis was completed for twenty-six pwHAM, (8♂; 18♀; median age: 57.8 years;
median disease duration: 8 years). Median time at baseline to: complete 10m was 17.5
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seconds, versus 21.4 seconds at follow up; 23% completed the 6MW compared to 42% at
follow up and a median distance of 55m was covered compared to 71m at follow up. Using
the 10mTW velocity to predict the 6MW distance, overestimated the distance walked in 6
minutes (p<0.01). Functional decline over time was captured using the functional ambula-
tion categories.
Conclusions
The 10mTW velocity underestimated the degree of disability. Gait speed usefully predicts
functional domains, shows direction of functional change and comparison with published
healthy age matched controls show that these patients have significantly slower gait
speeds. The measured differences over 18 months were sufficient to reliably detect change
and therefore these assessments can be useful to detect improvement or deterioration
within broader disability grades. Walking capacity in pwHAM should be measured using the
10mTW for gait speed and the 6MW for endurance.
Introduction
HTLV-1-associated myelopathy (HAM) is a non-remitting, slowly progressive inflammation
of the spinal cord, affecting approximately 3% of the 5–10 million HTLV-1 infected individuals
worldwide[1;2].The condition is characterised by proximal, more than distal, motor weakness;
lower limb spasticity, pain and bladder, bowel and sexual dysfunction[3]. Activity limitations
in people with HAM (pwHAM) include: walking; stair climbing; washing and dressing and
bladder management[4]. The aim of disease modifying treatment is to improve or preserve
function or to slow functional decline in all areas, especially walking.
HAM related disability has been assessed by several categorical scales. Aberlado and col-
leagues used the Functional Independence Measure /Functional Assessment Measure (FIM/
FAM) to describe the disability profile of pwHAM, highlighting locomotion, stair climbing and
bowel and bladder management4. Franzoi and Aberlado employing the Ambulation Function
classification and the American Spinal Injury Association Lower Extremity Motor Scores
(ASIA LEMS) identified knee extension and plantar flexion as strong correlates for community
ambulation[5]. Other measures used include the Expanded Disability Status Scale (EDSS),
Osame’s Disability Scale (ODS)[6] and the Evandro Chagas Clinical Research Institute (IPEC)
scale[7].
Walking, a complex task, is a fundamental function facilitating independence and allowing
multiple interactive experiences with the environment[8]. As a most basic activity of daily liv-
ing (ADL) it places demands on the nervous, cardiovascular and musculoskeletal systems,
which may singularly or collectively, have an effect on walking capacity[8;9;10]. Persons with a
neurological impairment aim to remain as independent as possible and impairment of gait
impacts both the level of activity and level of participation[11]. For many people with neuro-
logical conditions, walking is what they most treasure, and want to regain, improve or preserve.
Categorizing the disability profile of patients, whilst useful given the non-remitting nature
of the disease, may not fully capture change to a patient’s functional independence. Further
details are needed to expand our understanding of the functional impact for pwHAM.
Walking speed over a short fixed distance mainly evaluates lower limb function and is con-
sidered representative of gait quality and motor function[12;13]. Wade and colleagues were the
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first to describe and document the specific use of a timed 10m walking test to monitor the
walking recovery of patients post stroke[14]. It is a pragmatic quick test, easily applied in most
clinical settings, requires minimal equipment and has good sensitivity to changes in gait speed.
Using the 10m timed walk (10mTW), Martin et al demonstrated that walking function deterio-
rated by an average of 4 seconds/10m/year in pwHAM[15].
The 6 minute walk test (6MWT), a modification of the 12 minute walk, was originally devel-
oped for cardiorespiratory patients to specifically evaluate and monitor their functional capac-
ity, establish prognosis and evaluate change in disease in relation to treatment[16;17;18]. It
measures walking endurance, is used as a standard assessment for functional capacity across a
variety of neurological conditions. Distance walked in meters in up to 6 minutes and the time
taken are recorded. 6MWT performance in pwHAM has not been documented.
Quantification of the endurance capabilities for pwHAM and understanding whether and
how this complements the documented use of the 10mTW within this patient cohort, will
potentially provide a means of quantifying the current functional ability of a pwHAM as it
relates to their activity. By detecting early functional decline clinicians can potentially offer dis-
ease modifying treatment sooner and preserve function for longer. The objective of this study
was to improve the management of pwHAM by better measurement of disease impact. The
primary aim was to explore the relative contributions of the 10mTW and the 6MWT in the
assessment of mobility in pwHAM and compare these with previously published healthy age
matched controls and to compare the 10m TWwith functional ambulation categories and
functional categories.
The second aim was to determine whether these measures could detect change over the
minimum time period specified.
Methods
The National Centre for Human Retrovirology (NCHR) at St Mary’s Hospital, Imperial Col-
lege Healthcare NHS Trust is the main referral centre for patients with HTLV infection in the
United Kingdom (UK). Founded in 1993 the need for comprehensive documentation of dis-
ease progression to include description of pwHAM's walking pattern and use of walking aids
was soon apparent. Objective measures such as the 10mTW and 6MWT were introduced to
document change in gait disability and are performed at each assessment.
Inclusion criteria
Patients were included in the study if they had HAM diagnosed according to WHO criteria
(WHO 1998); had measures performed at least 11 months apart and were able to walk a mini-
mum of 10m on both occasions.
Exclusion Criteria
Patients with HAMwere excluded if they were unable to mobilise 10m at baseline and or follow
up using their usual walking aid.
The results of prospectively recorded routine clinical assessment of gait (6MTW; 10mWT
and walking aids) and pain were abstracted from the case notes of pwHAM, attending the
NCHR between 2009–2014. Pain was measured using a self-reporting, 11point, 10cm visual
analogue scale (VAS). Potential disease modifying therapies were documented. Disease modi-
fying therapies are defined as treatments that affect the underlying pathophysiology of the dis-
ease. For our patient cohort this would include the immunosuppressive agents: ciclosporin,
methotrexate or methyl prednisolone.
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The 6MWT assessment was performed at a single site using 10m repeats with turns along a
13.5 meter long, smooth, flat, uncluttered corridor and no encouragement was provided[19]
with patients being instructed to: ‘walk for as long as you are able’. Patients were not provided
with a rest break and once they stopped walking, irrespective of whether they completed the 6
minutes, the test was ended. In the 10mTW, the time taken (seconds) to walk 10m, with a
dynamic start, in the same environment was recorded. For both assessments, gait speed was at
the patient’s normal pace using their usual walking aid, no physical assistance was provided
and time was recorded using a digital stopwatch. Using age and height, predicted performance
for the 6MWT in the absence of disease, was calculated using reference formula for an unre-
peated 6 minute walk[20]. Comparisons between the gait speed of patients with HAM were
made to those of healthy age matched control data[21].
Functional ambulation categories were calculated based on the modified system proposed
by Perry et al[22] for those with post stroke walking disability both at home and within the
community. The functional ambulation categories, use a specific gait speed range to categorise
participants from household ambulation(0–0.4m/second), the most dependent category, to
limited community ambulation(>0.4m/second-0.8m/second) and finally to community ambu-
lation(>0.8m/second-1.2m/second), which is the most independent category [22]. The func-
tional categories related to gait speed were 0–0.2m/second indicating the need for discharge to
a nursing home if hospitalized; if gait speed was greater than 0.2m/sec up to1.4m/sec then the
patient could be considered for discharge home; those with gait speeds of 0–0.6 m/sec were at
greater risk of falls and were dependent for their activities of daily living and those with gait
speeds of 1.2m/sec-1.4m/second had normal walking speed to cross a road[23;24].There are
many variables associated with safely crossing a road including, but not limited to: managing
obstacles, increasing gait speed; walking in a crowd and negotiating curbs[24].
Statistical Analysis
Anonymised data were analysed in Excel and using SPSS-20 (Chicago, Illinois). Assessment of
the data for normality showed a positively skewed distribution. Descriptive statistics, intra-
patient comparison of distance, time, velocity and pain at the two time points was performed
using non-parametric tests (Wilcoxon’s Test), Spearmans correlation coefficients and one way
ANOVA to determine inter-variable relationships and linear regression to determine interde-
pendence of variables between the dependent variable (6MWT distance) and independent vari-
ables (10m velocity; pain; walking aid; anti-inflammatory treatment) were performed. A p
value of 0.05 or less was considered statistically significant.
Ethics
In the United Kingdom clinical research is governed by the National Research Ethics Service.
The current study was conducted under the auspices of Communicable Disease Group
Research Tissue Bank which was approved by NRES reference 09/h0606/106. In this research
project patients consent to the collection of clinical samples, and the utilisation of their clinical
data for research. Patients attending the National Centre for Human Retrovirology are pro-
vided with an information sheet about this research and all participants included in the study
provided written informed consent.
Results
During 2009–2014 26 pwHAMmet the assessment criteria. Median age was 57.8 years (Range:
26–83.3 years); 51.2% were Afro-Caribbean, 23.8%White and 21.4% other ethnicity. Median
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disease duration was 8 years (Range: 1–27 years). The median interval between the analysed
tests was 18 months.
Baseline 10mTW
The median 10mTW time was 17.45seconds (Table 1). The median velocity of 0.6 meters/sec-
ond (m/s) was significantly slower compared to 1.4 m/s of published healthy age matched con-
trols (p =<0.001) (Table 1). Velocity varied according to walking aid usage:1.0m/s for those
walking unaided; 0.5m/s for patients using one walking stick and 0.4 m/s for those using two
walking sticks or a walking frame. In this cohort of pwHAM, over a distance of 10 meters: 9/26
(35%) had a median velocity of 0.3m/s classifying them as household ambulators; 9/26 (35%)
had a median velocity of 0.6m/s—limited community ambulators and 8/26 (31%) had a
median velocity of 1.0m/sec—community ambulators (Table 2). With walking speeds of
0–0.6m/s 53% were deemed to have a falls risk, being 1.5 times more likely to fall compared to
healthy community dwelling people, including being dependent for ADLs. Only six pwHAM
met or exceeded 1.0m/s which is the recognised cut off velocity for healthy individuals. If hos-
pitalised, 92% of this cohort, by virtue of having walking speeds between 0.2–1.4m/s would be
discharged home whilst the 8% with 0–0.2m/s walking speeds would be discharged to a nursing
home. Only three, with walking speeds of 1.2–1.4m/s were sufficient agile to safely cross a street
(Table 3).
Change in 10mTW after median 18 months Follow up
The median 10mTW duration increased to 21.4 seconds, a deterioration of 4 seconds (p 0.05)
with the median 10mTW velocity decreasing by 25% to 0.45m/s (p 0.04). The walking speed
for those walking unaided (1.0m/s) and for those using one walking stick (0.5m/s) remain
unchanged; for those using two walking sticks velocity slowed from 0.4 to 0.3m/s and for those
using walking frames to 0.2m/s. Five cohort members met or exceeded the recognised healthy
cut-off speed of 1.0m/s. The number of patients classified as household ambulators increased
to 13, with an increase of 0.1m/sec in the median velocity. One less patient was classified as a
limited community ambulator, those classified as community ambulators decreased to five but
had an increased median walking speed of 1.2m/sec (Table 2). The number of patients deemed
at falls risk increased by 20%. If hospitalized 8% fewer pwHAM would be discharged home
(Table 3). Still only three patients had sufficient walking speed to safely cross a street (Table 3).
6 minute walk at Baseline (Table 1)
The median distance of 55m with a median walking time of 116.8s resulted in a median veloc-
ity of 0.5 m/s. Using age, height and weight the expected median distance walked should be
623.7m whereas the 6MWT distance based on the 10mTW velocity was predicted to be 260.5m
(p =<0.01). Thus, compared with predicted values the functional exercise capacity of the
cohort, as measured by the 6MWT, is severely impaired (p =<0.01). 23% of the cohort com-
pleted the 6MWT.
6 minute walk at Follow up (Table 1)
The median distance walked had significantly increased by 16m to 71m (p 0.02). The median
time spent walking increased by 167.2s (p =<0.001) to 284s. The median predicted distance in
the 6MWT, based on 10mTW velocity was 169.6m. An additional 19% of the cohort, 42% in
total, completed 6 minutes however velocity had decreased by 0.1m/s to 0.4 m/s. Calculating
the predicted 6MW distance using the patient’s 10mTW velocity, overestimates the actual
Walking Capacity in HTLV-1 Associated Myelopathy
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distance patients walked in 6 minutes at both time points (p =<0.001; p =<0.001). With an
intra-class correlation coefficient of 0.83, the 6MW shows good reliability over time.
The median increase in the 6 minute walk distance between the 2 time points could have
been skewed by the 6 pwHAM who had significantly increased their walking distance over the
2 time points. Without these 6 patients, the median 6 minute walk distance between the 2 time
points decreased by a median of 10.8m.
At both time points the 10mTW strongly, significantly, inversely, correlated with the
6MWT distance covered (rs = -0.78 p =<0.001;rs = -0.71 p =<0.001) and the 6MW velocity
(rs = -0.95 p =<0.001; rs = -0.92 p =<0.001), indicating that a deteriorating 10mTW resulted
in less distance covered for the 6 minute walk (Table 4). [Results reported separately for base-
line and 18 month assessments].
The velocities of both the timed 10mTW and the 6MWT, significantly and strongly correlated
at both time points (rs = .93 p =<0.001; rs = .77 p =<0.001)(Table 4).The stepwise forward
regression prediction model for the 6MW distance was statistically significant, accounting at base-
line for 32% (F = 0.13; p =<0.001) of the variance and 63% (F = 0.41; p =<0.001) by follow up.
There were weak, non-significant correlations, for age (rs = .00 p = .95;rs = .01 p = .95);
height (rs = .10 p = .62;rs = .00 p = .98); weight (rs = -.04 p = .84; rs = -.22;p = .28) and duration
Table 1. Descriptive Data Analysis of all 26 individuals.
Variable 1st Time PointRangeMedianStd Deviation
(SD) Standard Error of the Mean (SEM) 95%
ConﬁdenceInterval
2nd Time Point RangeMedianStd Deviation
(SD) Standard Error of the Mean (SEM) 95%
Conﬁdence Interval
% ChangeRangeStd
Deviation (SD) Standard
Error of the Mean (SEM)
P
Value
6 Minute
Walkdistance
covered in meters
10m-391mMedian:55mSEM:19.6195% CI:
55.77–136.54
15-443mMedian: 71mSEM: 24.5095%
CI:78.05–178.99
-77.97–460%Median:
16mSEM: 29.66
.02
Walking time
completed in the
6min walk test in
seconds
32.20-360secMedian:116.80
secSEM:22.5495% CI:127.53–220.37
37.70-360secMedian: 284 secSEM: 21.0895%
CI: 213.58–300.43
-63.89–757.14%Median:
55.3 SEM: 34.30
< .01
Time taken to
complete 10m TW
6.70–87.80secMedian:17.45SEM:3.4695%
CI:15.38–29.61
7.40–126.20secMedian:21.40SEM:6.4695%
CI:18.49–45.12
-30.9–318.6%Median:
20.3%SEM:16.90
.05
6 min walk Velocitym/
sec
0.10m/sec-1.10m/secMedian:0.50m/secSEM:
0.0595% CI: 0.40–0.61
0.10–1.20m/secMedian:0.40m/
secSEM:0.0695% CI: 0.33–0.57
-79.91–39.71%Median:
-14.10%SEM: 6.12
.03
10m Timed Walk
Velocitym/sec
0.10m/sec-1.50m/secMedian:0.60m/
secSEM:0.07m/sec95% CI: 0.51–0.81
0.10m/sec-1.40m/secMedian:0.45m/
secSEM:0.0795% CI 0.42–0.71
-76.11–44.78%Median:-
16.9%SEM: 6.07
.04
Pain Categories 0-9Median: 3.25SEM:0.7495% CI: 2.13–5.16 0-10Median: 1.50SEM: 0.7495% CI: 1.86–4.98 -100-400%Median: 0%
SEM: 17.34
.74
Disease Modifying
Therapies
1 patient ciclosporin 1 patient ciclosporin3 patients commenced
methotrexate
Estimated 6 Minute
Walk Distance Using
individuals age,
height, weight
(Troosters et al)
643.20m (486.40m – 880m)Median: 623.71SD:95.24SEM: 18.6895% CI: 606.63–679.86 < .01
doi:10.1371/journal.pone.0157132.t001
Table 2. Functional Ambulation Categories.
Gait Speed Meters/second (m/s) /Functional Ambulation
Category
Baseline N(%) Median Gait speed
(m/sec)
Follow Up N(%) Median Gait speed
(m/sec)
% Difference
0–0.4m/s = Household Ambulation 9(35%) 0.3m/s 13(50%) 0.4m/s 15%
0.4–0.8m/s = Limited Community Ambulation 9(35%) 0.6m/s 8(31%) 0.6m/s -4%
0.8–1.2m/s = Community Ambulation 8(30%) 1.0m/s 5(19%) 1.2m/s -11%
doi:10.1371/journal.pone.0157132.t002
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of disease (rs = -.29 p = .14; rs = -.36 p = .07) with the 6MW distance(Table 4). The one way
ANOVA for gender and the distance walked in the 6 minute walk test was not significant at
either time point (p = 0.78; F0.74; p = 0.72;F = 0.12).
Between baseline and follow up:19 pwHAM continued using the same walking aid; 2
pwHAM needed less help walking (i.e. from using 2 crutches to a walking stick) and 5 pwHAM
needed more help to walk progressing to a more dependent walking aid category.
Walking aids strongly and inversely correlated with the 6MW velocity (rs = -.78 p =<0.001;
rs = -.86 p =<0.001) and 10mTW velocity (rs = -.77 p =<0.001; rs = -.87 p =<0.001).
(Table 4).
The use of a walking aid impacted on the 6MW distance covered at time point 1(p = 0.04)
and more so at time point 2; p = 0.009). By the second time point 7 patients had changed their
walking aid, 2 of the 7 patients needed less help to walk and 5 of the 7 patients needed more
help to walk.
Disease Modifying treatment (DMT)
Only 4 patients were taking disease modifying therapy at either assessment point 1 patient on
ciclosporin throughout; 3 patients had initiated methotrexate by the second time point. These
numbers are too small for separate analysis.
Pain
Pain was not a significant variable throughout.
Discussion
The data demonstrate the value that gait speed and its stratification into functional categories
using velocity cut off points can add to the assessment of the walking ability of pwHAM. The
Table 3. Functional Categories.
Gait Speed Meters/second (m/s) Functional Category Baseline N (%) Follow Up N (%) % Difference
0–0.6m/s Falls Risk; Dependent for Activities of Daily Living 14 (54%) 19 (73%) 19%
0–0.2m/s Discharge to Nursing Home 2 (8%) 4 (15%) 7%
0.2–1.4m/s Discharge Home 24 (92%) 22 (85%) -7%
1.2–1.4m/s Normal walking speed to cross a street 3 (12%) 3 (12%) 0%
doi:10.1371/journal.pone.0157132.t003
Table 4. Correlation Analysis at the 2 time points (N = 26).
Spearman’s Rho Time Point(T) 6 Min Walk Distance Pain Timed 10m Velocity 6 Min Walk Velocity Disease Modifying Treatment
Timed 10m Walk T1 r = -.78p = <0.01* r = -.20p = .31 r = -.95p = <0.01* r = .30p = .12
T2 r = -.71p = <0.01* r = -.05p = .79 r = -.92p = <0.01* r = .20p = .32
6 Min Walk Distance T1 r = .10p = .61 r = .75p = <0.01* r = -.38p = .04*
T2 r = -.12p = .53 r = .71p = <0.01* r = -.07p = .71
Pain T1 r = .21p = .28 r = .08p = .67 r = -.03p = .88
T2 r = -.02p = .89 r = .03p = .86 r = .22p = .26
Timed 10m Velocity T1 r = .93p = <0.01* r = -.32p = .10
T2 r = .94p = <0.01* r = -.23p = .25
*. Correlation is signiﬁcant at the 0.05 level (2-tailed) r < = 0.3: Weak correlation; r> = 0.5: Moderate Correlation; r > = 0.7: Strong Correlation
doi:10.1371/journal.pone.0157132.t004
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6MWT captures the poor functional walking capacity in this cohort of pwHAM. Linking walk-
ing speed and walking distance to function allows interpretation against a meaningful reference
framework for comparison of functional status across patient populations and the ability to
monitor function[19;23;24;25].
Gait Speed
The data are consistent with the Martin et al[15] study demonstrating a median 4 second dete-
rioration of the 10mTW over 18 months. This deterioration was meaningfully illustrated when
patients were stratified into functional ambulation categories. Over time, despite a seemingly
gradual deterioration in the 10mTW, the functional impact is significant, highlighted by the
direction of transition and therefore deterioration, from community ambulation to the depen-
dent household ambulation category. Despite having the highest level of functional ambula-
tion, the median gait speed only reached 1.0m/s, which is the cut-off for healthy individuals.
When using ambulation categories to compare across condition types, the gait speed in this
cohort was slower (0.3m/s) than Kempen and colleagues’ patients with MS (0.5m/s) for those
in the household ambulation category despite both groups evenly matched (pwHAM 1.0–
1.2m/s and pwMS 1.3m/s) within the community ambulators[11].
Functional impairment is inversely associated with the odds of disability in both personal
and domestic ADL’s[8;9;26,27;28;29;30;31;32,33,34].For those individuals who are already
functionally impaired, 0.6m/s is a cut off for identifying risk of further functional decline
[26;28]. Applying this cut off to our pwHAM emphasizes their functional dependence and the
need for assistance with ADL’s for the majority of the cohort. The 0.2m/s median deterioration
of gait speed in our pwHAM, is double the proposed minimal detectable change value of 0.1m/
s for those who lack normal gait speed; and similar to pwMS[8;35].
Patient’s functional ability can further be explored by using gait speed (<0.7m/s) to predict
falls risk and up to 70% of our pwHAM, had a 1.5 times increased risk of falls[24]. This risk is
higher than the published prevalence of falls in mobile pwHAM (53%) and in older adults
(54%)[29;36;37].
Only three patients, at either time point, had sufficient velocity (1.2–1.4m/s), to cross a road
safely[23]. This velocity does not necessarily take into account the complex dynamics of step-
ping off a curb, walking in a crowd, paying attention to obstacles and traffic which are compo-
nents of dual tasking and may further reduce walking speed[24].
A systematic review assessing walking speed in clinical research, revealed that despite its
common use as an outcome measure it is limited by variance in how it is conducted[13]. The
results show the advantage of using the 10mTW velocity to highlight functional decline, those
at risk of falls and those requiring assistance with ADL.
6 Minute Walk Test
The 6 minute walk is a measure of functional capacity that includes, but is not limited to,
endurance, fatigability and cardiovascular fitness[38]. Our results emphasize that functional
exercise capacity for pwHAM is severely impaired compared to predicted age matched norma-
tive values[20]. The increase in median distance walked between the 2 time points, was not
expected in pwHAM., None of the patients were actively engaged in a physical activity or reha-
bilitation programme. Only 1 patient was on disease modifying therapy at both timepoints and
3 patients had initiated disease modifying therapy at the second time point.
However the increased distance could be attributed to the 6 patients who had a dramatic
increase in their distances walked, of which 2 were on disease modifying therapies at the second
time point. When these 6 patients are removed the median distance walked increased by only
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6metres. Although age, weight, height and gender might be expected to contribute to the vari-
ability in the distance walked in 6 minutes in healthy adults[20], this was not the case here.
In pwHAM, as in pwMS and pwStroke, the distance covered in the 6MW and the time
taken to walk 10m, are highly, inversely correlated[39].This potentially implies that the same
aspect of walking capacity is being measured[38;39;40]. However using the 10m velocity to pre-
dict the 6 minute distance significantly over estimated the latter in our cohort. This might be
due to the inability of pwHAM to maintain their walking velocity. The 10mTW and the
6MWT appear to represent different indicators of walking efficacy in pwHAM, with the longer
6MWT potentially capturing fatigue that is not picked up by the shorter measure. Therefore
using the 10MTW and 6MWT concurrently, for our pwHAM, does not support the notion of
redundancy.
Other Factors
Walking speed is further influenced by the use of walking aids, as demonstrated by the strong
correlation, at both time points, in our pwHAM. Our data agree with the studies reviewed by
Hornyak et al[8] indicating that the use of a walking aid may modify the relationship between
walking disability and self- selected walking speed[40], further masking the extent of their
neuro-disability.
Limitations to the Study
Space is at a premium in a clinical setting and in our clinic, we only have access to a 13.5m long
smooth corridor. Shorter corridor lengths necessitate more turns and this may result in addi-
tional energy loss, which may have been the case in our patient sample[18;41]. As with most
rare diseases, patient numbers for research purposes may be small, and the small sample size of
our patient cohort attests to this, therefore lacking sufficient numbers to adequately power the
study. Although the data points were a median of 18 months apart, patients were seen more
frequently (monthly to 3 monthly) and the walking tests were conducted at these visits, poten-
tially contributing to a learning effect.
Summary
The functional walking capacity of pwHAM can be usefully measured using the 10mTW for
gait speed and the 6MWT for endurance. Due to their functional deterioration, pwHAM
mainly transition from community ambulators to household ambulators. The severity of their
neuro-disability is highlighted by their slower household gait speeds, high dependence for
ADL’s, a 1.5 fold greater likelihood of falling and insufficient gait speed to cross a road. Impor-
tantly, using 10m gait speed to predict the 6MW distance, overestimates the actual distance
pwHAM walked. PwHAM have lower functional walking capacity compared to pwMS and
age, weight, height and gender does not explain the variability in the 6MWT. The median dete-
rioration in gait speed over 18 months is double the recommended minimal detectable change
score of 0.1m/second.
Conclusion
10mTW and 6MWT in pwHAM provide distinct information and significant changes can be
detected over a short a period as 11 months and therefore these assessments can be useful to
detect improvement or deterioration within broader disability grades. The 10mTW velocity
underestimated the degree of disability. Comparison with published healthy age matched con-
trols show that these patients have significantly slower gait speeds. Gait speed predicted
Walking Capacity in HTLV-1 Associated Myelopathy
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functional ambulatory capacity and risk related to falls and dependence on ADL and shows
direction of functional change. Walking capacity in pwHAMWalking capacity in pwHAM
should be measured using the 10mTW for gait speed and the 6MW for endurance. Therefore
the routine use of these measures in pwHAM could be used to formulate baseline assessments,
allow comparisons over time, as well be as used in prospective clinical trials.
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